Cetera Advisors’s Arcus Biosciences RCUS Stock Holding History

Cetera Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,212	Closed	-$228K	–	1780
2023 Q2	$228K	Sell	11,212 -671	-6%	-$12.8K	﹤0.01%	1444
2023 Q1	$217K	Buy	11,883 +1,410	+13%	+$26.9K	﹤0.01%	1457
2022 Q4	$217K	Buy	+10,473	New	+$288K	﹤0.01%	1405

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Cetera Advisors's RCUS Position: Q3 2023 in Review

Cetera Advisors sold out of Arcus Biosciences (RCUS) in Q3 2023, closing a stake of 11,212 shares — an estimated $228K sold.

Cetera Advisors first reported a position in RCUS in Q4 2022 and held it in 3 quarters. The position peaked at $228K in Q2 2023. 187 funds tracked by Wall St. Rank hold RCUS as of Q3 2023.

Cetera Advisors reported no remaining Arcus Biosciences position as of Q3 2023 after selling out during the quarter.
Cetera Advisors sold 11,212 Arcus Biosciences shares in Q3 2023, an estimated $228K.
Cetera Advisors first reported a position in Arcus Biosciences in Q4 2022 and held it in 3 quarters.
Cetera Advisors's Arcus Biosciences position peaked at $228K in Q2 2023.
187 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2023.

Based on Cetera Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.